Readoutin 76d
Janssen Research & Development, LLC — Nipocalimab
Phase 3 primary completion: Nipocalimab in Moderate to Severe Sjogren's Disease.
- Date
- Feb 2027
- Type
- Readout
- Indication
- Sjogrens Syndrome
Readoutin 76d
Phase 3 primary completion: Nipocalimab in Moderate to Severe Sjogren's Disease.
The weekly brief is free. Pro adds reminders 7 days and 1 day before.